Assenagon Asset Management S.A. Sells 101,021 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Assenagon Asset Management S.A. cut its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 18.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 452,093 shares of the company’s stock after selling 101,021 shares during the period. Assenagon Asset Management S.A.’s holdings in Pacira BioSciences were worth $8,517,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. American Century Companies Inc. raised its stake in shares of Pacira BioSciences by 16.6% in the second quarter. American Century Companies Inc. now owns 69,498 shares of the company’s stock worth $1,988,000 after buying an additional 9,911 shares during the period. Dimensional Fund Advisors LP increased its holdings in Pacira BioSciences by 12.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock worth $52,300,000 after acquiring an additional 198,936 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its stake in Pacira BioSciences by 39.0% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 12,686 shares of the company’s stock worth $363,000 after acquiring an additional 3,562 shares during the period. Hsbc Holdings PLC lifted its holdings in Pacira BioSciences by 74.6% during the second quarter. Hsbc Holdings PLC now owns 28,733 shares of the company’s stock valued at $812,000 after purchasing an additional 12,275 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Pacira BioSciences in the second quarter worth $140,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

PCRX stock opened at $22.36 on Monday. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $34.01. The firm has a market capitalization of $1.03 billion, a P/E ratio of -11.01 and a beta of 0.76. The company has a fifty day simple moving average of $18.71 and a two-hundred day simple moving average of $17.44. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Analyst Upgrades and Downgrades

PCRX has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Royal Bank of Canada reiterated a “sector perform” rating and set a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Needham & Company LLC boosted their price target on Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Barclays cut their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a report on Tuesday, November 12th. Finally, Jefferies Financial Group boosted their target price on shares of Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $24.50.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.